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1.  INTRODUCTION 
 The emergence of antibiotic resistance is a health problem 
worldwide and has affected the management and outcome of wide 
spectrum of infections. It contributes to significant mortality and 
morbidity and remains a hinderance to the control of infectious diseases. 
It leads to increase in health associated expenses and also acts as a barrier 
in the healthcare security of countries.1 Now-a-days, the need for newer 
antibiotics to treat infections caused by Gram positive organisms is being 
increasingly felt. 
 Globally, Staphylococcus aureus (S.aureus) is considered as one of 
the most common cause of nosocomial infections. This remains as the 
hardiest of the non-sporing bacteria and can survive well in the 
environment under both moist and dry conditions. The high prevalence of 
S.aureus, together with its propensity to infiltrate tissues, colonize foreign 
body material, form abscesses and produce toxins, makes it by far the 
most feared micro-organism in healthcare-associated infections.  
 In recent times, there is a steady rise in the number of S.aureus 
isolates that show resistance to Methicillin and has evolved as a serious 
problem since resistance to this drug indicates resistance to all β-lactam 
antibiotics. Multiple use of antibiotics and prolonged hospitalisation are 
important factors which make hospital an ideal place for transmission and 
perpetuation of Methicillin Resistant S.aureus (MRSA).2 For these above 
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reasons, accuracy and promptness in the detection of Methicillin 
resistance plays a key role for good prognosis of infections and hence 
abrupting its transmission.3 
  1.1. Historical importance   
    Sir Alexander Ogston, a Scottish surgeon in 1880, showed that a 
number of human pyogenic diseases were associated with a cluster-
forming micro-organism and introduced the name ‘Staphylococcus’.  In 
Greek, ‘staphyle’ means bunch of grapes and ‘kokkos’ means berry. Von 
Daranyi, in 1925 was the person to identify the coagulase test for 
S.aureus.4 
1.2. Morphology  
   Staphylococci are placed in the family Bacillaceae of the order 
Bacillales. S.aureus is a Gram positive, uniformly spherical cocci of 
0.5µm to 1.5µm in diameter on light microscopy and tends to occur in 
irregular grape-like clusters and less often, singly, pairs, tetrads, and short 
chains. This is due to the incomplete cell division in three perpendicular 
planes. In liquid media, singles, pairs and short chains are also seen. They 
are facultative anaerobes, nonmotile, non-sporing, and catalase positive.5 
1.3. Cultural characteristics  
 Colonies of S.aureus are medium to large, smooth, low convex, 
entire, glistening, densely opaque  and of butyrous consistency and are   
β- hemolytic on sheep blood agar at 37˚C when incubated for 18- 24 
4 
 
hours. The colonies of S.aureus are usually deep golden yellow (aureus 
means golden) and pigmentation can be enhanced on fatty media such as 
Tween agar, by prolonged incubation and at room temperature. On 
Mannitol salt agar it forms 1mm diameter yellow colonies surrounded by 
yellow medium due to acid formation.5 
1.4. Biochemical reactions 
  S.aureus ferments a range of sugars of which the significant one is 
mannitol. Acetoin production, gelatinase and alkaline phosphatase are all 
typically positive. Indole is negative while urease and lactose 
fermentation are variable characters. It produces a deoxyribonuclease and 
a thermonuclease.5 S.aureus gives a positive test for bound coagulase 
(clumping factor). It produces free coagulase which clots plasma by 
converting fibrinogen to fibrin and this property is used as a criterion in 
clinical laboratories to diagnose pathogenic S.aureus. 
1.5. Habitat           
 S.aureus is found in the anterior nares of 20-40% of the adults and 
also in the intertriginous skin folds, the perineum, the axilla and the 
vagina.6Decreased ciliary action and attachment to cell associated and 
cell free secretions favour its adhesion to nose.7  
 
 
 
5 
 
1.6. Pathogenesis 
 The bacterium can form biofilms, the tool which helps in the 
invasion of the defense mechanisms. The microcapsule of this bacterium 
has ‘zwitterionic’ characters and also paves way for formation of 
abscess.8The protein A of S.aureus attaches to the Fc portion of 
immunoglobulin and by this process opsonization can be 
inhibited. S.aureus produces leukocidins which leads to the production of 
pores in the cell membrane and hence lysis of the leukocyte.9 
 During infection, enormous enzymes are released, such as 
proteases, lipases and elastases which directs its progression to ultimate 
destruction. Some isolates produce superantigens, which produces 
“cytokine storm”, resulting in food poisoning, scalded skin and toxic 
shock syndrome.10  
 1.7. Mode of transmission  
 Nasal carriers of S.aureus have a three to six time’s higher risk of 
nosocomial infection than non-carriers.11 S.aureus is transmitted from 
person to person by direct contact, fomites, air or unwashed hands of 
health care workers in nosocomial setting. Respiratory droplets and skin 
squames released from the patients are other possible mechanisms for 
MRSA transmission in hospitals.12 When newborns are colonized by 
these organisms, the nursing mothers are at risk of developing mastitis.13   
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1.8. Infections 
 S.aureus may cause a variety of infections ranging from mild to 
life-threatening serious illnesses. Infections generally involve intense 
suppuration and necrosis of tissue. This organism is frequently isolated 
from postsurgical wound infections.6 S.aureus can be recovered from 
almost any clinical specimen. The infections14 caused by this organism 
are as follows: 
 Skin and soft tissue- Impetigo, boils, carbuncles, abscesses, 
cellulitis, fasciitis, pyomyositis, surgical and traumatic wound 
infections. 
 Foreign body associated- Intravascular catheter, urinary catheter, 
surgical implant, endotracheal tubes. 
 Intravascular- Bacteraemia, sepsis, septic thrombophlebitis, 
infective endocarditis. 
 Bone and joints- Septic osteomyelitis, septic arthritis.  
 Respiratory -Pneumonia, empyema, sinusitis, otitis media. 
 Other invasive infections- Meningitis, surgical space infection. 
 Toxin mediated diseases- Staphylococcal toxic shock syndrome, 
food poisoning, staphylococcal scalded skin syndrome, bullous 
impetigo, necrotizing pneumonia, necrotising osteomyelitis. 
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1.9. Risk factors 
  S.aureus can act as a significant opportunistic pathogen under the 
following conditions6 given below: 
 Defects in leukocyte chemotaxis, either congenital or acquired 
like Job’s Syndrome or diabetes mellitus. 
 Defect in opsonization by antibodies.  
 Defects in intracellular killing of bacteria following 
phagocytosis. 
 Skin injuries like burns, surgical incisions, eczema etc. 
 Presence of foreign bodies like sutures, intravenous line etc. 
 Infection with other agents, particularly viruses.  
 Chronic underlying diseases such as malignancy, alcoholism. 
 Therapeutic or prophylactic antimicrobial administration.     
 1.10. Evolution of MRSA                     
 Oxacillin and Methicillin are semisynthetic Penicillins that are 
stable to staphylococcal β-lactamase by virtue of the strategic placement 
of certain side chains on the molecule. These drugs were developed 
specifically for the treatment of infection caused by β -lactamase 
producing S.aureus. In 1959, the drug Methicillin was introduced and the 
bacterium just needed six months to create resistant strains to it.15  
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1.11. Mechanism of resistance 
1.11.1. Penicillin Binding Proteins 
 Under normal conditions, five Penicillin Binding Proteins (PBP) 
namely PBP1, PBP2, PBP2B, PBP3 and PBP4 are produced by the 
Methicillin Susceptible S.aureus (MSSA) isolates.16But an additional one, 
PBP2a is produced by the Methicillin resistant isolates and they differ 
from other PBPs, in the low affinity exhibited towards the β-lactam 
antibiotics. 
1.11.2. Staphylococcal Cassette Chromosome mec  
 Methicillin resistance is conferred by the mecA gene, which is a 
part of a mobile genetic element called Staphylococcal Cassette 
Chromosome (SCC) mec. SCCmec is flanked by cassette chromosome 
recombinase genes (ccrA/ccrB or ccrC), that allow transmission of 
SCCmec.10 Currently, six unique SCCmec types (I-VI) ranging in size 
from 21–67 kb have been identified and are distinguished by the variation 
in mec and ccr gene complexes.17 
1.11.3. The mecA gene 
   The mecA gene encodes the 78-kDa PBP2a.18 The mecA is under 
the control of two regulatory genes, mecI and mecR1. mecI is usually 
bound to the mecA promoter and functions as a repressor. In the presence 
of a β-lactam antibiotic, mecR1 initiates a signal transduction 
cascade that leads to transcriptional activation of mecA.19  
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1.12. Hospital acquired-MRSA and Community Acquired-MRSA  
 Hospital acquired (HA)-MRSA is usually associated with persons 
who have had frequent or recent contact with hospitals or other long-term 
care facilities such as nursing homes and dialysis centers. Community 
acquired (CA)-MRSA was isolated from indigenous Australian patients. 
Table - 1.1 
Characters of HA-MRSA and CA-MRSA strains15 
Character HA-MRSA CA-MRSA 
 Clinical 
presentation 
 Invasive and commonly 
surgical site infections 
Rarely invasive and 
commonly skin and 
soft tissue infections  
Predominant 
age  
Old aged Young people  
 
Target group Immuno-compromised Healthy persons 
Antibiotic 
resistance  
Multi-drug resistant β-lactam resistant 
Resistance 
gene  
SCCmec I-III 
 
SCCmec IV, V 
 
Presence of 
PVL 
Absent 
 
Present 
 
 
1.13. Laboratory diagnosis  
 Disc diffusion (DD) methods are the most widely followed 
procedures, in routine clinical laboratories. The acronym MRSA, is still 
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followed due to its historic role. The drugs Oxacillin and Cefoxitin are 
tested instead of Methicillin because: 
 Methicillin is not manufactured now-a-days. 
 Oxacillin maintains its activity better during storage.  
 More likely to detect heteroresistant strains.  
1.13.1. Heteroresistance:   
 Although, both susceptible and resistant cells are present in the 
culture, only a small number of cells express the resistance. Conditions 
that favour the heteroresistance are : 
 Neutral pH 
 Cooler temperatures (30–35˚C) 
 Presence of NaCl (2–4%) 
 Prolonged incubation (up to 48 hours). 
 The following methods are standard ones for detecting Methicillin 
resistance as per The Clinical and Laboratory Standards Institute (CLSI)15  
 Cefoxitin disc test  
 Latex agglutination test   
 Oxacillin screen agar. 
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1.13.2. Oxacillin DD method 
 Good visual interpretation with Oxacillin disc, may help in the 
detection of highly heteroresistant strains. Most isolates are deemed as 
sensitive, due to the hazy zones produced. This method can’t be relied 
due to its lower specificity.18 
1.13.3. Oxacillin screen agar 
 Although this test is called a “screen” the results can be considered 
definitive for assessing Oxacillin resistance in S. aureus. The sensitivity 
of this method, approaches 100% for the detection of MRSA.18  
1.13.4. Cefoxitin DD method 
 DD by Cefoxitin is easy to predict than other conventional 
methods. Only the isolates exhibiting mecA-mediated resistance are 
strongly induced and are reliably picked up by this method.20 However, 
non-mecA mediated Methicillin resistance in S. aureus is a rare 
occurrence.  
1.13.5. Broth dilution method 
 Though considered as a standard test for MRSA, this method has 
been replaced by the molecular techniques. More than 90% of the 
resistant strains are detected by the broth micro dilution method under 
appropriate conditions.18  
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1.13.6. E-test 
 The E-test method has the advantage of being easy to perform, as a 
disk diffusion test and its accuracy approaches that of PCR.21 
 1.13.7. Latex agglutination test 
 This method involves extraction of PBP2a from colonies and their 
detection by agglutination with latex particles coated with monoclonal 
antibodies to PBP2a. These tests are accurate and are faster than the 
conventional methods. Latex tests involves lysis/extraction, 
centrifugation to pellet cellular debris and mixing of the supernatant with 
the test and control latex reagents.6 
1.13.8. Chromagar 
 In recent years, the chromogenic media has been emerging as a 
boon, for the reliable and faster detection of Methicillin resistant isolates. 
These media allow direct colony color-based identification of the bacteria 
and thus is an upcoming technique. This saves time in subculturing the 
isolate and further reactions and is indeed the need of the hour. 
1.13.9. Automated systems 
 Automated systems have definitive role in the diagnosis of the 
Methicillin resistant isolates but sensitivity is not equal to that of the 
standard procedures.18They are:  
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 Microscan conventional panels (Dade Behring ) 
 Phoenix (Becton Dickinson) 
 Vitek ( bioMerieux) 
 1.13.10. Polymerase chain reaction   
 Polymerase chain reaction (PCR) is considered the “gold standard” 
for detection of Methicillin resistant isolates. The detection of non-
expressed mecA along with its rapid techniques makes it a reference 
technique in the laboratories for detection of Methicillin resistance. 
Recently addition of a second gene in addition to mecA, helps in the 
detection of resistance to various antibiotics among MRSA isolates. 
 1.13.11. GeneXpert  
 The target of the assay, is the junction of the SCCmec cassette and 
orfX.22The test is easy to follow and could be performed within five 
minutes and is therefore suitable for MRSA point of care testing.23 
1.13.12. Phage typing 
 Strains of S.aureus can be differentiated into different phage types 
by observation of their pattern of susceptibility to lysis by a standard set 
of S.aureus bacteriophages. Virulent phages cause lysis of staphylococci 
and thus produce a clearing in the lawn of growth. Many strains of 
MRSA are non-typable with standard and additional phages.13 
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1.14. Control of MRSA  
1.14.1. Need for control of MRSA  
The control of MRSA, is important for the reasons given below: 
 High transmission. 
 Treatment with multidrugs are expensive. 
 Side effects are higher.  
 Poorer prognosis.  
 Limited number of oral agents available.24  
1.14.2. Control measures 
Hand hygiene 
                Alcohol-based hand rubs/gels or using soap and water should 
be adhered strictly. This is the initial and major step in preventing 
transmission. 
Patient isolation 
  An infected or colonized patient should be placed in separate 
rooms as far as possible and barrier precautions are to be followed. 
Contact precautions 
 The health-care provider should wear gloves, apron and adhere to 
strict hand hygienic procedures. 
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Droplet precautions 
 Surgical masks are to be worn when the need to work closely with 
the patient arises. In patients with skin exfoliative lesions, masks are 
advised during bed making. 
Decolonization of patients/ carriers 
 Eradication of MRSA carriage is not always successful. Topical 
intranasal mupirocin and fusidic acid are to be installed. 
Environmental cleaning 
 Regularly clean with an all-purpose detergent and water and make 
sure that all horizontal surfaces are damp dusted and floors vacuumed. 
 The incidence of Methicillin resistance is a growing problem in the 
hospitals worldwide. Accurate and speedy techniques are vital for 
treating, managing, and preventing MRSA infections. Effective detection 
of MRSA can be difficult in simple clinical laboratories because 
susceptible and resistant populations may coexist in the same culture.     
Conventional methods are numerous and the choices in selection and 
application varies, among laboratories. Many phenotypic methods fail to 
detect Methicillin resistance and the sensitivity pattern of the isolates 
remains unpredictable among hospitalized patients. So a faster and cost-
effective ideal method, which detects all MRSA strains is of utmost 
necessity. With this background, this study is undertaken to assess the 
prevalence, antimicrobial sensitivity patterns and to evaluate various 
16 
 
conventional and molecular methods for effective MRSA detection 
among clinical isolates. 
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2. AIMS AND OBJECTIVES 
 
2.1. To study the antimicrobial sensitivity pattern of S.aureus among pus      
        samples at Tirunelveli Medical  College, Tirunelveli. 
2.2. To determine the prevalence of MRSA among the clinical isolates. 
2.3. To evaluate Chromagar for detection of MRSA. 
2.4. To confirm the MRSA isolates by Real- Time PCR for mecA gene.                                                           
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3. REVIEW OF LITERATURE 
  “Antibiotic resistance in S.aureus was not known when Penicillin 
was first introduced in 1943, by Alexander Fleming who observed the 
antibacterial activity of the penicillium mould against a culture of 
S.aureus.25 S.aureus remains as one of the most dangerous nosocomial 
pathogens. MRSA is the strain of S.aureus that had developed, through 
the process of evolution, resistance to β-lactam antibiotics.  
 The resistance of MRSA to more common antibiotics makes it a 
difficult organism to be handled and thus are more dangerous. The 
association of multidrug resistance with MRSA adds to the problem and 
it is rightly said that “hospital dust is most dangerous than roadside dust” 
and the danger is from MRSA.26 
3.1. Epidemiology 
 The resistance of S.aureus to Methicillin varies from region to 
region and is also not similar at different times in the same hospital. 
MRSA has been reported all over the world. MRSA has emerged globally 
in the last three decades, especially within hospital settings. 
3.1.1. Global scenario of MRSA 
 In 1961, Jevons did screening of 5000 clinical isolates and 
identified three MRSA isolates from England.27 In United States, the first 
outbreak of MRSA occurred in 1968, at the Boston City Hospital.                 
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 Blot et al 2002, had found more deaths among MRSA bacteremia 
than MSSA.28 In United States, 50% of hospital acquired infections in 
ICUs are due to MRSA.29  
 According to a European Antimicrobial Resistance Surveillance 
System report, MRSA was held responsible for 0.5 to 44% of cases of 
staphylococcal bacteremia in Europe and the highest incidence of 44% in 
Greece and lowest of 0.5% in Iceland.30   
  In 2010, encouraging results from a CDC, showed that life-
threatening MRSA infections are declining. Invasive MRSA infections 
that began in hospitals decreased 28% from 2005 to 2008. Decreases in 
infection rates were even more for patients with bloodstream infections. 
In addition, the study showed a 17% decrease in invasive MRSA 
infections of community onset in people with recent exposures to 
healthcare settings. This report complements data from the National 
Healthcare Safety Network. They found declining rates of upto 50% in 
bloodstream infections occurring in hospitalized patients from 1997 to 
2007.31 
 3.1.2. MRSA in India 
 In Asia, MRSA averages 70% of hospital-acquired S. aureus 
isolates, but paucity of information remains from most regions. In India, 
the prevalence of MRSA is increasing drastically among hospitals, and is 
approximately 30% of S. aureus infections.32The reported incidence of 
22 
 
MRSA in India was found to range from 26% to 51.6%.33 Overall the rate 
of Methicillin resistance among large hospitals in India with S. aureus is 
nearly 32%.2  
 A study by Verma et al34 2000, had shown the highest prevalence 
of 80.78% among 484 S.aureus isolates tested at Indore. Tahnkiwale et 
al35 2002, did a study from Nagpur on 230 S.aureus and found the 
prevalence of MRSA to be 19.56%. The study done by Mulla et al36 2007 
at Surat, had shown the prevalence of MRSA among 135 staphylococci as 
39.5%.  
 The prevalence rate was 7.5 to 41% among three hospitals in New 
Delhi. (Gadepalli et al37 2009).The study by Pal et al38 2010, from Jaipur 
stated that the prevalence of MRSA was 7% only, among S.aureus 
isolates. The study from Ujjain, found the prevalence to be 16% (Pathak 
et al39 2010).  
3.1.3. MRSA in Tamil Nadu 
 Reports on MRSA isolates are very scanty in Tamil Nadu. So 
MRSA, remains an underestimated problem and effective measures are 
not a important measure in the hospital. Rajaduraipandi et al40 2006, from 
Coimbatore, found that the 250 (31.1%) were MRSA positive among 906 
S.aureus isolates.  
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 A study from Chennai, had screened 298 suspected septicemic 
children and isolated 54 bacteremic children. S.aureus constituted 26 of 
them and the prevalence of MRSA among them was 10 (38.46%).  
( Saravanan et al25 2009) .                                 
 The study by Thangavel et al41 2011, from Namakkal revealed that 
10 (7.9%) were MRSA out of 126 clinical isolates while the remaining 
were MSSA and coagulase negative staphylococci. 
3.2. MRSA distribution according to age and gender 
 A higher prevalence rate was seen among females (60.86%) than in 
the males (39.13%) in the study by Sharma et al42 2011. Mathanraj et al43 
2009, found that the male gender was a significant factor in the study 
conducted with 17 (8.5%) of MRSA isolates. Males had a prevalence of 
12.4% (15/118) while females had 2.4% (2/82) only. 
3.3. Risk factors 
 Initially, infections due to MRSA were almost acquired in 
healthcare settings. The most common risk factors associated with MRSA 
were recent antibiotic intake, admission to emergency care units, surgery, 
and exposure to another patient colonized with MRSA. 
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3.3.1. Nasal carriage 
 In the study by Kumar et al7 2011, the carriage rate of S.aureus was 
33 among (82.5%) doctors and seven among laboratory technicians 
(17.5%)  while that of MRSA was 15 among doctors (83.3%)  and three 
among lab technicians (16.6%).          
 3.3.2. Prolonged stay at hospital and antibiotic therapy  
 The study by Srinivasan et al44 2006 found the following factors to 
be associated with MRSA: prolonged postoperative treatment, recent 
antibiotic use and emergency admissions in the hospital. Seventy percent 
of the isolates were from postoperative cases undergoing emergency 
surgeries. Isolation was more during the second week of hospital stay. 
Emergency admissions had a significant risk of chance of early isolation. 
Prior treatment with multiple antimicrobials (38%) was found to be 
another significant factor.  
3.3.3. Old age and Diabetes 
 Huijer et al45 2008, found that most of the MRSA isolates from 
surgical units were from aged and diabetic patients. This reflects the 
waning effect of the immune system. This may be due to the delay in  
discharge and prolonged antimicrobial treatment at hospital which results 
in enhanced antibiotic pressure. 
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3.3.4. Race 
 A study by Sedik et al46 2009, from USA had found out that by 
race, African-American patients were most likely to acquire MRSA 
infections (47%), followed by Caucasians (35%), Hispanics (31%), and 
Asian/Pacific Islanders (24%). 
3.3.5. HIV 
 HIV infected persons (14%) are at higher chance of acquiring 
MRSA infection than non-HIV infected (3%) ones. Prolonged intake of 
Co-trimoxazole has been reported to be associated with S.aureus 
colonization.  Recent antibiotic intake, CD4 T cell count < 200/mm3, 
presence of indwelling catheter, presence of skin lesions and prolonged 
stay at hospital are the risk factors associated with HIV to be infected by 
MRSA.47 
3.4.6. Burns 
 Marked immunosuppresion with indwelling catheters and 
endotracheal tubes, longer admissions at hospitals and the open wound 
itself are important factors which favour MRSA acquisition. 
 The study by Matsumura et al48 1996, found a prevalence of 15% 
among adults and children in burns patients. In the study by Roberts et 
al49 1998, 39.4% of MRSA infections occurred in burns unit. 
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3.4.7. Surgery 
 Srinivasan et al44 2006, from PIMS found that surgical units 
accounted for 40 (80%) of the MRSA isolates when compared to the 10 
(20%) in medical units.  Hujer et al45 2008, showed that majority of the 
MRSA isolates was from surgical units. 
3.4.8. Job’s syndrome  
 This autosomal disorder presents with cold abscess which are 
prone for infections with S.aureus especially MRSA.50 
3.5. Distribution on the basis of infection 
 The study by Mehta51 et al 1998, made observation of the isolation 
rate of MRSA and found it to be 33% from pus and wound swabs. 
Quershi et al52 2004, found a high isolation rate of 83% MRSA from pus. 
Rajaduraipandi et al40 2006, from Coimbatore found that out of the 1847 
pus samples, 575 (31.1%) were S.aureus isolates and MRSA isolates 
were found to be 193 (33.6%). The study done by Mulla et al36 2007, had 
shown that out of the total 20 S.aureus ,11 were found to be MRSA 
among pus samples, followed by blood (five MRSA among 11 S.aureus) 
and one MRSA isolate each from other samples.  
 The study by Thangavel et al41 2011, from Namakkal revealed that 
out of the total 48 (38%) samples from wound, three (30%) were MRSA 
and the 12 (24%) were MSSA among males while two (20%) were 
MRSA and the eight (16%) were MSSA among females .The study 
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revealed that out of the total 47 (37%) samples from pus, 15 (30%) were 
MSSA and three (30%) were MRSA among males while seven (14%) 
were MSSA and one (10%) was MRSA among females. 
 Terry Alli et al53 2012, from Nigeria revealed that out of 48 MRSA 
isolates, 12 (21.4%) were from the wound swab and eight (40%) from eye 
and ear swabs. Karami et al21 2011, studied 106 MRSA isolates, 51 (48%) 
strains isolated from tracheal aspirate, 26 (24.5%) strains from wound, 10 
(9.4%) strains from blood cultures, and 19 isolates (17.9%) from other 
specimens. 
3.6. Antibiotic resistance of MRSA isolates 
  A few and important hallmarks of drug resistance are discussed 
below. 
3.6.1. Penicillin 
 At the end of 1940, hospitals in England and the USA reported that 
up to 50 % of S. aureus strains were resistant to Penicillin. In 1950, 40% 
of hospital S. aureus isolates were Penicillin resistant; and by 1960, this 
had risen to 80%.21 
3.6.2. Co-trimoxazole 
 The use of this drug has a magnificient role as an alternative to 
Vancomycin in serious MRSA infections. Rajaduraipandi et al40 2006, 
found that 63.2% were resistant among MRSA isolates. The study Hujier 
et al45 2008, showed 32 (21.3%) showed resistance and 118 (78.7%) 
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isolates were sensitive. A total of 96% resistance were observed among 
MRSA isolates (n=27) to Vancomycin by Sarma et al54 2010. 
3.6.3. Vancomycin 
 Vancomycin was discovered in the 1950s and was initially used to 
treat Penicillin resistant staphylococci and other Gram-positive bacterial 
infections. The first isolate of Vancomycin intermediate S.aureus  (VISA) 
emerged in 1996, from Japan. Complete resistance to the drug was 
observed from a patient in 2002, from Michigan.55 
 3.6.4. Multidrug resistance 
 MRSA are considered resistant to all penicillinase-stable 
Penicillins and β-lactam agents. MRSA usually are resistant to multiple 
classes of agents including Macrolides, Lincosamides and Tetracyclines. 
They also can be resistant to Fluoroquinolones and Aminoglycosides. 
 In the mid of sixties, occurrence of multidrug-resistant MRSA was 
reported world wide including India. The ability of IS431 elements, 
through homologous recombination, to trap and cluster resistance 
determinants with similar insertion sequence elements explains the 
multiple drug resistance that is characteristic of MRSA.18  
 The drugs Ciprofloxacin, Clindamycin, Gentamicin and 
Vancomycin should be initiated only after antibiotic sensitivity testing. It 
is not entirely certain why some strains are highly transmissible and 
persistent in healthcare facilities. 
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 In the study by Tahnkiwale et al35, multidrug resistance was 
evaluated and the following resistance was observed among MRSA 
isolates: 97% for Cotrimoxazole and 93.3% for Chloramphenicol. Only 
6.66% of the isolates showed resistance towards Gentamicin. All isolates 
were found to be susceptible to Vancomycin. 
 Arora et al,26 found that 73% of the MRSA strains were resistant to 
≥ 3 drugs. Majority of the isolates were resistant to Cephalexin (80.9%) , 
followed by Gentamicin (72.2%), Ciprofloxacin (67.8%), Erythromycin 
(61.7%) and Amikacin (37.4%). A 100% sensitivity was observed to 
Vancomycin. 
3.7. Evaluation of various methods in laboratory identification of 
MRSA 
 Diagnostic Microbiology laboratories play a pivotal role in 
identifying earlier, isolates of MRSA. The bacterium must be generally 
cultured initially, for performing the confirmatory or reference methods.  
3.7.1. Role of temperature and duration in MRSA detection 
 Laboratory methods have been developed to enhance the 
expression of resistance in staphylococci. So supplementation of media 
with Nacl and extending the incubation time increases the detection rate. 
 A study from Delhi, compared Cefoxitin DD with Oxacillin DD 
method among 155 S.aureus isolates. Cefoxitin disc identified 54.54% 
MRSA isolates and Oxacillin disc method identified 48.39% only. There 
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was no difference in zone diameter at 18 hours and 24 hours of 
incubation. (Gupta et al56 2009). 
 Kluytmans et al57 2002, evaluated Chromagar for Methicillin 
resistance. The sensitivity at 24 hours was 58.6% and at 48 hours it was 
higher (77.5%). The specificity at 24 hours was 99.1% and at 48 hours it 
was lower (94.7%). 
 Hal et al58 2007 from Sydney, compared Chromagar with PCR. 
The sensitivity of Chromagar for MRSA detection increased 8% only, 
with extended incubation to 48 hours. Specificitiy was 99% at 24 hours. 
However, the specificity decreased with 48 hours of incubation. 
3.7.2. Evaluation of Cefoxitin DD method 
 A study from Sweden, evaluated the performance of a Cefoxitin 
30µg disc on Iso-Sensitest agar, for detection of MRSA. A total of 457 
S.aureus, including 190 MRSA isolates were confirmed by PCR. They 
concluded that the Cefoxitin method was excellent, with a sensitivity of 
100% and a specificity of 99%. (Skov et al59 2003) 
   In the study by Hujer et al45 2008, MRSA detected by the DD test 
and PCR assay were identical. Consequently, the sensitivity and 
specificity of Methicillin DD test as compared to mecA gene PCR are 
therefore 100% respectively. Similarly, the sensitivity and specificity of 
Cefoxitin DD method in detecting MRSA as compared to mecA gene 
PCR were 97% and 97.4% respectively. 
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 The study by Bhat et al60 2008, collected 210 S.aureus isolates and 
tested them for MRSA by agar screen method and DD method. A total of 
69  (33%) isolates were MRSA by agar screen method and 59 (28%) by 
DD method. The use of higher bacterial density and the presence of Nacl 
in the medium may help in the better detection of MRSA by agar screen 
method. They concluded that the disc method is unreliable for Methicillin 
resistance detection.                                        
 Rao et al61 2011 from Karnataka, revealed that out of the 300 
S.aureus isolates, 50 were found to be MRSA by both Cefoxitin DD and 
PCR while 48 isolates only were picked up the Oxacillin DD method. 
The sensitivity and specificity of Oxacillin disc method was 90% and 
100% respectively and the same for Cefoxitin disc method was 100% 
respectively and were in concurrence with the PCR for mecA gene. They 
concluded that Cefoxitin DD test can be used as an alternative to PCR.   
3.7.3. Evaluation of Chromagar 
 A study from Switzerland, had compared four chromogenic media 
for their efficacy with PCR. Out of the 247 clinical isolates, 70 were 
found to be MRSA. The Chromagar identified a maximum of 64 of the 
MRSA isolates and a minimum of 37.The maximum and minimum 
sensitivity and specificity were 91% and 53% and 95% and 68% 
respectively.(Cherkaoui et al62 2007).     
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 A study from UK, had compared Chromagar with PCR for 
effective MRSA detection. A total of 148 isolates (12.3%) were MRSA 
positive, of which 146 (12.1%) were PCR positive and 128 (10.6%) were 
Chromagar positive. A total of 126 (10.5%) were both PCR and 
Chromagar positive and 20 (1.66%) were positive by PCR only while two 
(0.2%) were positive by Chromagar only. They concluded that PCR is 
very much sensitive than Chromagar for MRSA detection.(Danial et al63 
2011).  
 Karami et al21 2011, from Tehran did a study comparing 
Chromagar with E-test as gold standard. Out of the total 294 S.aureus, 
106 (36%) were found to be MRSA. Chromagar showed 110 isolates as 
MRSA. The sensitivity and specificity for the Chromagar were 100% and 
97.9% respectively and Positive Predictive Value (PPV) and Negative 
Predictive Value (NPV) were 96.3% and 100% respectively. 
3.7.4. PCR 
 The study by Mehndiratta et al642009, did typing of 125 MRSA 
isolates by bacteriophage  and PCR-RFLP of spa gene. DNA sequencing 
analysis was performed and all the isolates had mecA gene. 52% were 
typeable and five patterns were observed. Among the non-typeable 
isolates, four different patterns were observed. 
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 The study from Switzerland, analysed 1,601 specimens for MRSA 
detection by PCR. The sensitivity, specificity, PPV and NPV were 
84.3%, 99.2%, 88.4% and 98.9% respectively.(Lucke et al65 2010) 
 The study from Saudi Arabia, had done multiplex PCR targeting 
16sRNA, PVL and mecA gene among 101 isolates. All the isolates were 
positive for 16sRNA and mecA gene. Only 38, of the isolates (37.6%) 
gave positive results for PVL gene. The predominant type were SCCmec 
type V 43 (42.5%) and type III 39 (38.6%).(Moussa et al662012) 
 3.8. Why are MRSA important? 
 Causes serious life-threatening infections.  
 Limited treatment options. 
 MRSA are transmissible. 
             The high pathogenicity, the few number of treatment options 
available and transmission among hospitals are the major factors which 
make MRSA, to be considered as a threat to patients. 
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4. MATERIALS AND METHODS 
 The present study was conducted at the Department of 
Microbiology, Tirunelveli Medical College, Tirunelveli for a period of 
one year from September 2011 to August 2012 to assess the drug 
sensitivity pattern of S.aureus isolates from pus samples, to determine the 
prevalence of MRSA and to evaluate Methicillin resistance by Cefoxitin 
DD method, Chromagar and its confirmation by Real-Time PCR. Various 
risk factors associated with the study group, were statistically analysed 
and results were interpreted.  
4.1. Materials  
4.1.1. Sample collection and processing 
  A total of 100, non-duplicate S.aureus isolates from clinical pus 
samples were taken into the study. The S.aureus isolates were identified 
by:  
 Morphology on Gram stained smear   
 Colony appearance on nutrient agar 
 Colony appearance on sheep blood agar 
 Positive catalase test 
 Positive tube coagulase test 
 Sensitivity to Furazolidone (100µg) 
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4.1.2. Ethical clearance  
 As this study involved the clinical samples from the patients, 
ethical clearance was obtained before the commencement of the study. 
4.1.3. Informed consent   
 Informed consent was obtained from all persons involved in the 
study. 
4.1.4. Proforma 
 A filled in proforma was obtained from the patients with details 
like name, age, sex, ward, clinical diagnosis, risk factors, surgical 
intervention, hospital stay and other parameters relevant to the study. 
4.1.5. Sample storage 
 The S.aureus isolates were sub-cultured on to nutrient agar slope 
and stored at 2 to 8˚C. The isolates were sub-cultured every month. 
4.1.6 .Safety precautions 
 All the procedures were carried out in a Biosafety cabinet with due 
precautions. 
METHODS 
4.2. Antibiotic sensitivity testing 
 All the S.aureus isolates were tested by DD method to detect 
Methicillin resistance and their antibiotic sensitivity pattern. 
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 4.2.1. DD method 
               DD method was performed by Kirby-Bauer method using 
Mueller Hinton agar with the following antibiotic discs (HiMedia 
Laboratories, Mumbai, India). 
 Penicillin(10IU)  
 Cefoxitin(30µg)  
 Erythromycin(15µg) 
 Clindamycin(2µg) 
 Gentamicin(10µg) 
 Amikacin(30µg) 
 Ciprofloxacin(5µg) 
 Cotrimoxazole(1.25/23.75µg) 
 Vancomycin(30µg) 
 Teicoplanin(30µg) 
 Tigecycline(15µg)  
 Linezolid(30µg) 
 Discs were stored in a tightly sealed container with dessicant at 
2°C to 8°C. Before opening the container, discs were allowed to 
equilibrate to room temperature for one to two hours to minimize 
condensation and to reduce the possibility of moisture affecting the 
concentration of antimicrobial agents. 
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4.2.2. Mueller Hinton agar   
 The Mueller Hinton agar was purchased from HiMedia 
Laboratories, Mumbai, India and media was prepared according to the 
manufacturer’s instructions (Appendix-I). Before inoculation, plates were 
dried by placing it in the incubator with their lids ajar, for 10–15 minutes. 
4.2.3. Inoculum preparation 
 Inoculum was prepared by direct colony suspension method by 
taking four to five well isolated colonies of S.aureus from 18-24 hours 
culture, in Mueller Hinton broth to achieve a turbid suspension. 
4.2.4. Inoculum standardization 
 The inoculum suspension was compared with 0.5 McFarlands 
standard suspension by positioning the tube side by side against a white 
card containing several horizontal black lines. The turbidities were 
compared by looking at the black lines through the suspensions. Once 
standardized, the inoculum suspension was used within 15 minutes of 
preparation. 
4.2.5. Principle of DD test 
 The principle of DD depends on the formation of a gradient of 
antimicrobial concentrations as the antimicrobial agent diffuses radially 
into the agar. The drug concentration decreases at increasing distances 
from the disc. At a critical point, the drug concentration at a specific point 
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in the medium is unable to inhibit the growth of the test organism and the 
zone of inhibition is formed. 
4.2.6. Procedure  
 After standardization of bacterial suspension, the suspension was 
vortexed to make sure, it was well-mixed.  
 Then by using a sterile swab, inoculation was done on Mueller 
Hinton agar and excess fluid was removed by pressing the swab 
against the side of the test-tube. 
 Swab was streaked evenly over the surface of the medium in 
three directions; the plate was rotated approximately 60° for 
even distribution.  
 With the petri dish lid in place, three to five minutes was allowed 
for the surface of the agar to dry.  
 Using sterile needle mounted in a holder, the appropriate discs 
were evenly distributed on the inoculated plate. 
 The discs were placed about 15mm from the edge of the plate 
and not closer than about 25mm from disc to disc.  
 Only six discs were applied on a 90mm plate. Each disc was 
lightly pressed down to ensure its contact with the agar.  
 The plate was inverted and incubated at 35˚C aerobically for full 
24 hours. 
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4.2.7. Interpretation of results 
      After incubation, the inhibition zone was measured to the nearest 
millimeter using a ruler, under transmitted light. Inhibitory zone includes 
the diameter of the disc. After measuring, the millimeter reading for each 
antimicrobial agent was compared with that in the interpretive tables of 
the CLSI guidelines67 and results were interpreted as either susceptible, 
intermediate or resistant. For Cefoxitin discs, zone size of  ≥ 22mm was 
taken as sensitive while zone size of ≤ 21mm was taken as resistant. 
(Table 4.1). 
Table.4.1. Interpretation of zone sizes 
S. 
No 
Antibiotic 
disc 
Disc 
strength 
Resistant 
(mm) 
Intermediate 
(mm) 
Sensitive 
(mm) 
1. Penicillin 10 IU ≤ 28 - ≥ 29 
2. Cefoxitin 30 µg  ≤ 21 - ≥ 22 
3. Erythromycin 15 µg ≤ 13 14-22 ≥ 23 
4. Clindamycin 2 µg ≤ 14 15-20 ≥ 21 
5. Gentamicin 10µg ≤ 12 13-14 ≥ 15 
6. Amikacin 30 µg ≤ 14 15-16 ≥ 17 
7. Ciprofloxacin 5 µg ≤ 15 16-20 ≥ 21 
8. Cotrimoxazole 1.25/23.
75µg 
≤ 10 11-15 ≥ 16 
9. Vancomycin 30 µg - - ≥ 15 
10. Teicoplanin 30 µg   ≤ 10      11-13       ≥ 14 
11. Tigecycline 15 µg     -      -       ≥ 20 
12. Linezolid 30 µg     -      -       ≥ 21 
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4.2.8. Quality control  
 The ATCC 25923 S.aureus strain, was included for each and every 
procedure performed. 
4.2.9. D-test 
 This test was done to detect inducible Clindamycin resistance. It 
was done by placing both Erythromycin (15µg), and Clindamycin (2µg) 
discs on Mueller Hinton agar plate with a distance of 15 mm edge to 
edge.  Following overnight incubation, flattening of the zone towards the 
Clindamycin disc with the shape of “D” indicated inducible Clindamycin 
resistance. 
4.2.10. Other considerations 
 All the isolates were confirmed for Vancomycin resistance by 
agar screen method. 
 An isolate of MRSA is considered to be multidrug resistant if it 
shows resistance to ≥ 3 drugs, excluding Penicillin and 
Cefoxitin. 
4.3. Chromagar 
 All the S.aureus isolates were inoculated onto Chromagar for 
detecting Methicillin resistance. 
 4.3.1. Principle 
 Chromogenic media detects the key microbial enzymes as 
diagnostic markers for pathogens through the use of “chromogenic” 
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substrates incorporated into a solid-agar-based matrix.68 The chromogenic 
mixture incorporated in the medium is specifically cleaved by MRSA 
isolates to form bluish green coloured colonies. 
4.3.2. Procedure    
 Four to five colonies of S.aureus from nutrient agar plate was 
streaked on the HiCrome MeReSa Agar with added MeReSa selective 
supplement (M1674 and FD299, HiMedia Laboratories, Mumbai, India)  
(Appendix-II) and incubated for 18-48 hours at 35ºC aerobically. 
4.3.3. Interpretation 
 Appearance of luxuriant bluish green colonies on the HiCrome 
MeReSa agar indicated that the isolate was MRSA while the Methicillin 
sensitive S.aureus colonies, were inhibited. Observation for growth of the 
colonies were made at 24 hours of incubation. The plates showing 
negative results were further incubated for 24 hours and read for coloured 
colonies. 
4.4. Real-Time PCR  
 The Methicillin resistant S.aureus isolates were further tested for 
mecA gene by Real-Time PCR by the kit purchased from Helini 
Biomolecules, Chennai, India and procedure followed according to the 
manufacturer’s instructions. 
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4.4.1. Safety precautions 
 All the procedures were done in a Biosafety cabinet Level-2 with 
due precautions. 
4.4.2. Equipments 
 Vortex mixer 
 Refrigerated centrifuge 
 Thermo cycler (Biorad CFX 96) 
 Computer for data storage 
4.4.3. DNA extraction 
 Each silica based spin column recovered up to 20µg of DNA and 
yielded purified DNA of more than 30 kb in size. Isolated DNA was used 
directly for PCR reaction. 
4.4.3.1. Components of extraction 
 Lyophilised Proteinase K 
 Proteinase K dilution buffer 
 Lysis buffer 
 Internal control template 
 Wash buffer-I 
 Wash buffer- II 
 Isopropanol 
 Elution buffer 
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4.4.3.2. Storage and stability 
 The kit was stored at 25˚C. 
 1ml of Proteinase dilution buffer was added to each 
Proteinase stock vial.  It was mixed well and stored at -20˚C. 
4.4.3.3. Sample preparation  
 Four to five colonies of S.aureus grown on nutrient agar plate was 
inoculated into five ml of nutrient broth. It was incubated overnight at 
35˚C. This was then transferred into three tubes, 1.5ml each. The tubes 
were then centrifuged for five minutes at 10,000 rpm. The supernatant 
was discarded and the bacterial pellet was stored at -20˚C. 
4.4.3.4. Principle of extraction 
 Cells are lysed during a short incubation with Proteinase K in the 
presence of chaotropic salt, which immediately inactivates all nucleases. 
Cellular nucleic acids bind selectively to special glass fibres, pre-packed 
in the spin column. Bound nucleic acid is purified in a series of rapid 
“wash and spin” steps to remove contaminating cellular components. A 
special inhibitor buffer removes all salts and inhibitors from the 
preparations. Finally low salt elution releases the nucleic acids from the 
glass fibre. 
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4.4.3.5. Extraction procedure                                                    
 All the steps were done at room temperature. 
 The bacterial pellet was suspended in 200µl of phosphate 
buffered saline and vortexed for 30 seconds. 
 Lysis buffer of 400µl and 5µl of internal control template 
was added to the suspension. 
 To the above suspension, 20µl of proteinase K was added. 
 This was mixed immediately by inverting and incubated at 
56°C for 15 minutes in a water bath. 
 200µl of Isopropanol was added and mixed well by inverting 
several times. 
 Entire sample was pipetted into a spin column. 
 This was centrifuged for one minute at 12,000 rpm. Flow 
through was discarded. 
 500µl of Wash buffer –Ι was added to the spin column. 
 This was centrifuged for 60 seconds at 12,000 rpm. 
Flowthrough was discarded. 
 500µl of Wash buffer-II was added to the spin column. 
 This was centrifuged for 60 seconds at 12,000 rpm and flow 
through was discarded. 
 The steps with Wash buffer-II was repeated again. 
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 The flow through was discarded and centrifuged for an 
additional one minute at 12000 rpm  to remove the residual 
ethanol. 
 The spin column was transferred to a fresh 1.5ml 
microcentrifuge tube. 
 50µl of the Elution buffer (pre-warmed to 70˚C) was added 
to the centre of the spin column membrane. Care was taken 
not to touch the membrane with pipette tip. 
 It was incubated for two minutes at room temperature and 
centrifuged for two minutes at 12,000 rpm. 
 The column was discarded and purified DNA was stored at 
 -20°C. 
4.4.4. PCR amplification  
4.4.4.1. Key ingredients for amplification  
QPCR probe mix  
 The QPCR probe mix contains the essential components for PCR 
amplification like DNA polymerase and deoxynucleotides. 
MRSA primer & probe mix 
 The MRSA primer & probe mix consists of TaqMan probe which 
is florescent labeled with FAM, forward primer and reverse primer. 
Forwardprimer-ACTGCTATCCACCCTCAAACAG 
Reverse Primer- CTGGAACTTGTTGAGCAGAGGTT 
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Internal Control primer & probe Mix             
 The internal control primer & probe mix consists of TaqMan probe 
which is florescent labeled with VIC, forward primer and reverse primer. 
The reason for including the internal control is to make sure that PCR 
inhibitors are not present in the extracted sample DNA and the 
performance of PCR mix ingredients are good. When no amplification 
was observed in internal control, it indicates that PCR inhibitors are 
present in the sample and efficiency of the nucleic acid purification is not 
optimum. It helps to rule out false negative results. 
MRSA positive template 
          To be used for positive control mix. 
Nuclease free water 
           For usage in negative control mix. 
4.4.4.2. PCR amplification kit storage 
 The kit was stored at -20˚C. 
4.4.4.3. MRSA reaction mix  
 The MRSA reaction mix for the samples consisted of QPCR 13µl, 
MRSA primer probe mix 2µl, internal control primer probe mix 1µl, 
purified DNA sample 5µl and a total volume of 21µl.(Table.4.2)  
            For positive control mix, 5µl of positive control template was 
added instead of sample DNA and for negative control mix, 5µl of 
nuclease free water was added instead of sample DNA.(Table.4.3& 4.4) 
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             Initially negative control, followed by samples and finally 
positive control was added to prevent cross contamination. After adding 
all the ingredients, they were centrifuged and placed in the thermo cycler 
and the PCR reaction was allowed to occur. 
Table.4.2.MRSA reaction mix for samples 
S. No Components Volume 
1. QPCR probe mix 13 µl 
2. MRSA primer probe mix 2 µl 
3. Internal control primer probe mix 1 µl  
4. Purified DNA sample 5 µl 
 Total volume 21 µl 
                                  
Table.4.3.MRSA Positive control mix 
S.No Components Volume 
1. QPCR probe mix 13µl 
2. MRSA primer probe mix 2µl 
3. Internal control primer probe mix 1µl 
4. Positive control template  5µl 
 Total volume 21µl 
                                                 
                      Table.4.4.MRSA Negative control mix 
S.No Components Volume 
1.  QPCR probe mix 13µl 
2. MRSA primer probe mix 2µl 
3. Internal control primer probe Mix 1µl 
4. Nuclease free water 5µl 
 Total volume 21µl 
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4.4.4.4. Basic steps in amplification 
 Initial denaturation - First, the temperature is raised to 
95˚C for four minutes for Taq enzyme activation. 
 Denaturation- When the temperature is raised to 95˚C for 
20 seconds, template DNA strand gets separated to two 
complementary strands. 
 Annealing- When the temperature reduces to 55˚C for 20 
seconds, two specific oligonucleotide primers binds to the 
DNA template complementarily. 
 Extension- When the temperature rises to 72˚C for 20 
seconds, DNA polymerase extends the primers at the 3’ 
terminus of each primer and synthesizes the complementary 
strands along 5’ to 3’ terminus of each template DNA using 
deoxynucleotides in the reaction mixture. After extension, 
two single template DNA strands and two synthesized 
complementary DNA strands combine together forming two 
new double stranded DNA copies.  
 Each copy of DNA may serve as another template for further 
amplification. The products will be doubled each cycle. After 40 cycles, 
the final PCR products will have 2n copies of template DNA.  Data 
collection was done at the end of extension and the computer generates 
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the cross threshold (Ct) value by calculating the fluorescence emitted at 
the end of each cycle. (Table 4.5) 
Table.4.5.Amplification profile for mecA gene 
 Step Time Temp 
Taq enzyme activation 
4 
min 
950 C 
 
40cycles 
Denaturation 20 
sec 
950 C 
Annealing/ Data 
collection 
20 
sec 
550 C 
Extension 20 
sec 
720 C 
 
4.4.5. Ct value   
 When Ct value was less than 37, it was considered as 
positive for mecA gene. 
 The test was repeated with Ct values between 37- 40. 
 Negative result if no amplification occured. (Table 4.6) 
                                    Table.4.6. Interpretation of results 
MRSA Negative 
control 
Positive 
control 
Interpretation 
Positive  Negative  Positive Positive 
Negative Negative  Positive Negative 
Negative Negative Negative Repeat 
Positive Positive Positive Repeat 
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5. RESULTS 
5.1. Study samples 
 The study was conducted at the Department of Microbiology, 
Tirunelveli Medical College, over a period of one year from September 
2011 to August 2012. A total of 100 S.aureus isolates from pus samples 
were included in the study. These isolates were further tested for 
Methicillin resistance by Cefoxitin DD test, Chromagar and Real-Time 
PCR. The antibiotic sensitivity patterns of the isolates and the risk factors 
were further analysed. 
5.2 Statistical Analysis  
 Data regarding the subjects were described in terms of percentages. 
The ages of the subjects were compared between the genders by student’s 
unpaired‘t’ test. The sensitivity, resistant and intermediately susceptible 
was described in terms of percentages. The multidrug resistance 
associated with Methicilin was interpreted by ‘Z’ test of proportions. The 
D-test was interpreted by paired chi-square test. The statistical procedures 
were performed with the help of the statistical software IBM SPSS 
statistics 20. The p values less than 0.05 was considered as significant (p 
<0.05) in two tailed test. 
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5.3. Analysis by age and gender 
Table 1. Sample distribution by age and gender 
Age 
(years) 
     Male       Female Total  
No % No % No % 
≤ 15  17 27.4 14 36.8 31 31 
16 – 30 10 16.1 06 15.8 16 16 
31 – 45 14 22.5 09 23.7 23 23 
46 – 60 12 19.3 06 15.8 18 18 
≥61 09 14.5 03 7.9 12 12 
Total 62 100 38 100 100 100 
  
 Out of 100 isolates, 62 isolates were from males and the remaining 
38 isolates were from females. A total of 31 isolates, fell in the study 
group of ≤ 15 years of which, 17 isolates (27.4%) were from males and 
14 isolates (36.8%) were from females. Out of the 16 isolates in the 16-30 
years age group, 10 isolates (16.1%) were from males and six isolates 
(15.8%) were from females. A total of 23 the isolates were in the 31-45 
age group, of which, 14 isolates (22.5%) were from males and nine 
isolates (23.7%) were from females.   A total of 18 isolates were in the 
46-60 years group, out of which 12 isolates (19.3%) were from males and 
six isolates (15.8%) were from females. Out of 12 isolates in persons 
above 61 years, nine isolates (14.5%) were from males and three isolates 
 (7.9%) were from females. The mean age of male was 36.9 years and that 
of female was 29.6 years and was n
 (p> 0.05).(Figure.1)   
Fig.1. Analysis of samples by age and gender
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5.4.1. Evaluation of cefoxitin DD method and Chromagar in detection 
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Fig.2 Methicillin resistance by Cefoxitin DD method and Chromagar
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5.4.3. Performance characteristics of Cefoxitin DD method & 
Chromagar                    
Table 4.Performance characteristics of conventional methods 
Method 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Cefoxitin DD 
test  
100 100 100 100 
Chromagar 100 100 100 100 
 
 The sensitivity, specificity, PPV and NPV of Cefoxitin disc method 
and Chromagar were 100%, 100%, 100% and 100% respectively. 
Chromagar was equally efficacious to Cefoxitin disc method for MRSA 
detection.(Table 4) 
5.5. Distribution of MRSA isolates by age and gender  
 Table 5 shows the distribution of MRSA isolates by age and gender 
distribution. Most of the MRSA isolates 36% were from ≤ 15 years of age 
of which all were boys. Three isolates (12%) were from males and two 
isolates (22.2%) were from females in the 16-30 years age group. In the 
31-45 years age group, five isolates (20%) were from males and four 
isolates (44.4%) were females among MRSA isolates. Six isolates (24%) 
were from males and two isolates (22.2%) were from females in the 46- 
60 years age group. Above 61 years, two isolates (8%) were from males 
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and an isolate (11.1%) was from female. The mean age of male was 30.7 
years and that of female was 39.2 years among MRSA isolates and was 
not significant. (p > 0.05) (Figure.4) 
            
Table 5.MRSA isolates by age and gender 
 
d.f= degrees of freedom 
                                  
  
Age 
in years 
MRSA 
Male Female 
No % No (%) 
≤ 15 09 36 0 0 
16 – 30 03 12 02 22.2 
31 – 45 05 20 04 44.4 
46 – 60 06 24 02 22.2 
≥61 02 08 01 11.1 
Total 25 100 09 100 
Mean     30.7      39.2 
S.D    23.1      15.6 
‘t’          1.017  
d.f          32 
p value          > 0.05 
 Fig.4. Distribution of MRSA isolates by age and gender
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               Table.6 shows the distribution of MSSA and MRSA isolates on 
outpatient and inpatient basis. Majority of the MRSA isolates were in the 
inpatient group. No significant difference was observed statistically.
(fig.5) 
Fig.5.MRSA isolates by inpatient and outpatient 
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5.7. Distribution of S.aureus among samples from various wards 
Table 7.MRSA isolation from wards  
Ward 
MRSA MSSA 
No % No % 
Surgery 11 32.3 21 31.8 
Paediatrics 7 20.6 13 19.7 
Orthopaedics 4 11.8 15 22.7 
O&G 3 8.8 3 4.5 
Dermatology 3 8.8 6 9 
ENT 1 2.9 9 13.6 
Ophthalmology 1 2.9 - - 
Neurosurgery 1 2.9 - - 
Medicine - - 2 3 
Total 34 100 66 100 
 
 The above table shows the distribution of MRSA samples from 
various departments of the hospital. Surgery department accounted for the 
majority of the MRSA isolates i.e 11 (32.3%) of the 34 isolates. Seven 
isolates were from paediatrics (20.6%), four from orthopaedics (11.8%), 
three from O&G (8.8%), three from dermatology (8.8%), one from ENT 
(2.9%), one from ophthalmology (2.9%) and an isolate from neurosurgery 
(2.9%). (fig.6). 
 
 
 Fig.6 Sample distribution of MRSA from various departments
 
5.8. Association of S.aureus
Table 8. MRSA categorization on infection basis
Infections
Wound infection
Surgical site 
infection 
Boil / Furuncle
Abscess 
Carbuncle 
Burns 
Ear discharge
Total 
  
11.8
8.8
8.8
2.9
62 
 with infections 
 
MRSA MSSA 
No % No %
 10 29.4 13 19.7
9 26.5 26 39.4
 7 20.6 6 9.1
5 14.7 9 13.6
1 2.9 1 1.5
1 2.9 2 3 
 1 2.9 9 13.6
34 100 66 100
32.3
20.6
2.9 2.9
Surgery
Paediatrics
Orthopaedics
O&G
Dermatology
ENT
Ophthalmology
Neurosurgery
 
 
 
 
 
 
 
 
 
 
 
  Table.8 shows that majority of the MRSA infections are associated 
with wound infection i.e. 10 (29.4%). Nine isolates from surgical site 
infection (26.5%), seven
(14.7%), one from carbuncle (2.9%), one from burns (2.9%) and an 
isolate from ear discharge (2.9%).
 
Fig.7.Association of infections with MRSA
 5.9. Duration of hospital stay  
 A total of 24 (75%) and eight
from patients with less than two
weeks respectively. The association of MRSA isolates with the duration 
of stay in hospital was not significant. 
 
20.6
14.7
2.9 2.9
63 
 from boil/ furuncle  (20.6%), five 
 (Fig.7) 
 
 
             
 (25%) of the MRSA isolates wer
 weeks stay in hospital and more than two 
(Table.9&fig.8) 
 
29.4
26.5
2.9
Wound infection
Surgical site infection
Boil / Furuncle
Abscess
Carbuncle
Burns
Ear discharge
from abscess 
 
e 
 Table 9. S.aureus
p > 0.05 
Fig.8. MRSA isolates by duration of stay at hospital
 
 
21.9
Duration in 
weeks 
<2 
>2 
Total 
64 
 isolates by duration of hospital stay
 
 
 
78.1
MRSA MSSA
No % No 
24 75 49 
8 25 13 
32 100 62 
 
 
 
<2 weeks
>2 weeks
 
% 
79 
20 
100 
 5.10. Association of risk factors with 
Table 10. MRSA and risk factors
Risk factors
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 The above table shows the association of risk factors for MRSA 
isolates. Surgery accounts for 9 (26
constitutes four (11.8%) of the isolates. Burns, HIV and Job’s syndrome 
accounted for each of an MRSA (2.9%) isolate respectively.
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5.11. Antibiotic sensitivity pattern of S.aureus 
Table 11. Antibiogram of S.aureus isolates 
 
Drug 
MSSA MRSA 
p value 
S  I  R  S  I  R  
Penicillin  04 - 62 0 - 34 < 0.05 
Cefoxitin 66 - - 0 - 34 - 
Erythromycin 21 40 05 02 11 21 < 0.05 
Clindamycin 46 17 03 11 05 18 > 0.05 
Gentamicin 44 04 18 07 03 24 > 0.05 
Amikacin 52 07 07  13 09 12 < 0.05 
Ciprofloxacin 21 16 29 04 08 22 > 0.05 
Cotrimoxazole 28 21 17 10 08 16 >0.05 
Vancomycin 66 - 0 34 - 0 > 0.05 
Teicoplanin 43 23 0 20 13 01 < 0.05 
Tigecycline 66 - 0 34 - 0 >0.05 
Linezolid 66 - 0 34 - 0 > 0.05 
 
S= Sensitive, I= Intermediate, R= Resistant 
Fig.10 and 11 depicts antibiogram of MRSA and MSSA isolates 
  
 5.11.1. Penicillin 
 Only four (6.1%) isolates 
remaining 62 (93.9%) isolates of MSSA and all the 34 (100%) isolates of 
MRSA were resistant to Penicilli
statistically significant.
5.11.2. Erythromycin
 Among MSSA isolates, 21 (31.8%) were sensitive, 40
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5.11.3. Clindamycin                  
 Among MSSA isolates, 46 were sensitive (69.7%), 17 were 
intermediate (25.6%) and three were resistant (4.5%) to Clindamycin 
(2µg). Eleven isolates were sensitive (32.4%), five were intermediate 
(14.7%) and 18 isolates were resistant (52.9%) among MRSA isolates. 
This was not statistically significant. 
 5.11.4. Gentamicin                 
 A total of 44 (66.7%) among MSSA isolates and seven (20.6%) 
among MRSA isolates were sensitive to Gentamicin (10µg). Four among 
MSSA (6%) isolates and three among MRSA (8.8%) showed 
intermediate susceptibility. Resistance was noted among 18 MSSA 
(27.3%) isolates and 24 (70.6%) MRSA isolates. This was not 
statistically significant. 
 5.11.5. Amikacin              
 A total of 52 (78.8%) were sensitive among MSSA isolates and 13 
(38.2%) among MRSA isolates to Amikacin (30µg). A total of seven 
(9%) were among MSSA and nine (26.5%) among MRSA isolates 
showed intermediate sensitivity. Resistance was noted among seven 
(10.6%) MSSA and 12 (35.3%) MRSA isolates. This was found to be 
statistically significant. 
  
 Fig.11
5.11.6. Ciprofloxacin                
 A total of 21 (31.8%) were sensitive among MSSA isolates and 
four (11.8%) among MRSA isolates
(24.2%) were intermediate among MSSA and eight (23.5%) 
MRSA isolates. Resistance was noted among 29 (44%) MSSA isolates 
and 22 (64.7%) MRSA isolates. This was found to be statistically 
significant. 
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(25.6%) MSSA isolates and 16 (47.1%) MRSA isolates. This was not 
statistically significant.  
5.11.8. Vancomycin 
 All the isolates were sensitive (100%) to Vancomycin (30µg) and 
none of them were resistant to the drug among MRSA and MSSA 
isolates. All the isolates were sensitive by Vancomycin agar screen 
method also. 
5.11.9. Teicoplanin 
 A total of 43 (65.2%) were sensitive among MSSA isolates and 20 
(58.8%) among MRSA isolates to Teicoplanin (30µg). Twenty three 
(34.8%) were intermediate sensitive among MSSA and 13 (38.3%) 
among MRSA isolates. Resistance was not noted among 66 MSSA 
isolates, but an isolate was resistant (3%) among MRSA. This was found 
to be statistically significant. 
5.11.10. Tigecycline  
 All the isolates were sensitive (100%) to Tigecycline (15µg) and 
none of them were resistant to the drug among MRSA and MSSA 
isolates. 
5.11.11. Linezolid 
 All the MRSA and MSSA isolates were sensitive (100%) to 
Linezolid (30µg) and no resistance was noted. 
 
 5.12. Inducible Clindamycin resistance         
 Inducible
Resistance 
MSSA 3
MRSA 12
Total 15
          p > 0.05 
 Table 12 shows, inducible C
isolates. Among the MSSA, three
resistance. But among MRSA
resistance. No significant difference was observed between MSSA and 
MRSA isolates. (fig.12)
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Table.12. D-Test 
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5.13. Multidrug resistance among MRSA isolates  
 An isolate of MRSA is considered to be multidrug resistant if 
resistance was noted among ≥ 3 drugs (excluding Penicillin and 
Cefoxitin) in this study. 
 
Table 13. Multidrug resistance 
 
No. of drugs MRSA isolate % 
≤ 2 13 38.2 
3 05 14.7 
4 05 14.7 
5 04 11.8 
6 07 20.6 
Total 34 100 
           
 Five MRSA isolates (14.7%) were resistant for ≥ three drugs, five 
isolates (14.7%) for four drugs, and four isolates (11.8%) for five drugs. 
Seven isolates (20.6%) were resistant for six drugs- Erythromycin, 
Clindamycin, Gentamicin, Amikacin, Ciprofloxacin and Co-trimoxazole 
in the present study. (Fig.13) 
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6. DISCUSSION 
 The early detection of Methicillin resistance is of prime importance 
in the prognosis of S.aureus infections. The identification of MRSA is 
determined by the method performed, which can vary in sensitivity and 
specificity. Factors that impact culture-based detection of MRSA include 
incubation time, temperature and accurate interpretation. Enhanced 
detection along with the cost effectiveness has a key role in clinical 
laboratories with limited resources. In this study, various methods are 
evaluated for detecting Methicillin resistance and PCR is considered the 
“gold standard” for detecting the mecA gene. 
6.1. Prevalence 
 Prevalence of MRSA in the present study was 34% among the pus 
samples. This is comparable with the study conducted by Buzaid et al,69  
from Libya where the prevalence was found to be 31%. The study by 
Srinivasan et al,44  found MRSA prevalence to be 33% which is similar to 
the present study. But the study by Sharma et al,42 from Himachal 
Pradesh found the prevalence rate to be 23.71%. 
 The study by Vidhani et al,70 found the prevalence among the high 
risk patients as high as 51.6%. Majumer et al,71 from Assam, observed 
52.9% prevalence of MRSA. But the study from Eritrea72 had only 9% 
prevalence of MRSA. 
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6.2. Distribution of MRSA isolates              
 In this study, majority of the MRSA isolates were from males 
(25%) while the remaining were females (9%). This is similar to the 
study by Thangavel et al,41 where males 30% constituted most of the 
MRSA isolates while 10% was from females. On contrary, the study from 
Doon valley hospitals,42 had showed that most of the MRSA isolates were 
from females 60.86% while males had 39.13% only. The study by Buzaid 
et al,69 found no significant difference between males 28 (31.8%) and 
females 34 (30.4%) among MRSA isolates. 
 Majority of the MRSA isolates was from the surgery department 
32.3%, followed by paediatrics 20.6%, orthopaedics 11.8%, and 
dermatology 8.8% in the present study. The study by Arora et al,26 too 
had found highest prevalence from surgical units (54.8%). Surgery was 
definitely an associated factor in MRSA infections as those patients are 
bound to take antimicrobials for long duration. The highest percentage of 
isolates were from Intensive Care Units (34%) in the study by Sadaka et 
al73.  Sarma et al,54 had found that MRSA was associated with 34% of 
infections in orthopaedics and 18% in surgical units but 1% in medical 
units. The study by from Amristar26 showed that, orthopedic patients 
accounted for the maximum number of MRSA strains (27.8%). 
 In this study, almost most of the MRSA were isolated from wound 
infection 29.4% while surgical site infections constituted 26.5%. The 
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remaining isolates were from boil/furuncle 20.6%, abscess 14.7% and 
burns 2.9%. This is comparable to the study by Terry Ali et al,53 where 
wound infection (21.4%), isolated majority of the MRSA isolates. The 
study from PIMS,44 found a high prevalence from post operative surgical 
infections (80%). Frazee et al,74 found that MRSA,was strongly 
associated with infection type- furuncle. 
6.3. Risk factors                   
 Most of the MRSA isolates were from patients who had undergone 
surgery 26.5%, while 11.8% isolates with diabetes, 2.9% with burns, 
2.9% with HIV and 2.9% with Job’s syndrome. Surgical site infections, 
both superficial and deep, could be caused by MRSA. Repeated surgeries 
and hence prolonged stayal, paves way for MRSA infections. Among 
diabetics, the decrease in the neutrophil activity plays a predominant role 
for MRSA infection. But the study from New Delhi75 found a 51.6% 
association with high risk patients like burns. This was attributed to the 
longer stay in hospital and the usage of multiple antibiotics. 
 No significant association was found between MRSA and MSSA 
isolates for treatment on outpatient and inpatient basis in the present 
study. The inpatients had the highest rate (15.6%) compared to the 
outpatients (3.8%) in the study from JIPMER.43 
 In this study, duration of stay at hospital was not a risk factor for 
MRSA infection. Similarly, the study from Northeastern India54 had 
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found that duration of hospital stay had no significant association with 
MRSA infection. But Mehta et al,51 observed significant association of 
MRSA and hospital stay of more than 15 days. 
6.4. Laboratory diagnosis                   
  Methicillin detection in laboratories is based upon a wide array of 
tests like conventional, Chromagar and molecular methods. The detection 
of mecA gene by PCR has stood best of time and is considered the “gold 
standard” technique for Methicillin resistance. PCR requires lesser time 
to perform and the results are rapid in few hours. But its limitations are: 
needs skills to perform, high cost and chance for cross contamination. 
6.4.1. Cefoxitin DD method                 
 In the present study, Cefoxitin DD method identified 34 MRSA 
isolates which were confirmed by PCR and had sensitivity, specificity, 
PPV and NPV of 100% respectively. The study by Rao et al,61 and Gupta 
et al,56 too found that all the MRSA isolates were identified by Cefoxitin 
DD method and is found to have 100% sensitivity and specificity.  
 Hujer at al45 found the sensitivity and specificity of 97% and 97.4% 
for Cefoxitin DD test. But the study from Egypt,73 found that the 
sensitivity and specifcity of Cefoxitin DD method to be 98.6% and 72.4% 
only, while the PPV and NPV were 89.7% and 95.5% respectively.               
 CLSI recommends Cefoxitin DD method for detecting Methicillin 
resistance in clinical laboratories. The method is easy to be carried out, no 
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special training is required and interpreting the zone sizes too is also not 
so difficult. But Cefoxitin DD method requires another 24 hours to detect 
Methicillin isolates after isolation of the organism and is unable to pick 
up the non-mecA mediated Methicillin resistance.   
6.4.2. Chromagar                 
 In this study, Chromagar identified 34 (100%) isolates from the pus 
samples at 24 hours of incubation itself and no isolates showed growth 
after 48 hours of incubation. The sensitivity, specificity, PPV and NPV 
were 100% respectively for Chromagar.  The study from Japan76 found 
the same results where the Chromagar  identified all the MRSA isolates 
and 100% sensitivity and specificity was determined. Van Hoecke et al,77 
found that Chromagar showed growth of all MRSA isolates at 24 hours 
itself, thus avoiding further incubation.  
 This is in contrast with the study by Kaur et al,78  where Chromagar 
misidentified 11 MSSA isolates as MRSA and had a sensitivity of 
77.27% and specificity of 79.25% only. In the study by Thangaavel et al41 
too, Chromagar identified 7 false positives. Paul et al,79 evaluated 
Chromagar with PCR for MRSA detection and found that at 24 hours the 
sensitivity and specificity were 85.4% and 99.4% which increased to 
87.7% and 100% at 48 hours of incubation.               
 Chromogenic medium had emerged as a newer method for 
selective and rapid detection of MRSA isolates. This method has the 
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added advantage of interpreting the result easily by observing the 
coloured colonies. They are developed with higher sensitivity and 
specificity too. It is ideal to use Chromagar in clinical samples so that 
detection of MRSA isolates can be earlier than the conventional methods. 
The disadvantage is the prolonged incubation if no growth occurs. 
5. Antibiotic resistance                
6.5.1. Penicillin               
 Only four (6.1%) isolates were sensitive to Penicillin among the 
MSSA isolates in the present study. This is comparable to the study by 
Vidhani et al,70 where six (5.5%) isolates were sensitive to Penicillin 
among MSSA isolates.  In the study bySarma et al,54 18% of the MSSA 
isolates were sensitive to Penicillin. 
6.5.2. Erythromycin                  
 Among the Macrolides, Erythromycin resistance seems to be on 
rise among MRSA isolates. In the present study, resistance was noted 
among 5 (7.6%) of the MSSA isolates while it was 21 (61.8%) among 
MRSA isolates. Arora et al,26 found that 61.7% of MRSA isolates were 
resistant to this drug. Frazee et al,74 and Rao et al,61 found 56.8% and 45-
48% resistance among MRSA isolates. This is in contrast to the study 
from Coimbatore,40 where the Erythromycin resistance was 20.5% only. 
The role of Erythromycin as an alternative among MRSA infections is 
uncertain because of higher resistance. 
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 6.5.3. Inducible clindamycin resistance              
 The present study showed the inducible Clindamycin resistance as 
12% and the constitutive resistance was 6% among MRSA isolates while 
the inducible Clindamycin resistance was only 3% among MSSA isolates. 
The D-test had identified 12 isolates which would had been considered 
sensitive to Clindamycin leading to inappropriate treatment. This is in 
comparable to the study by Sireesha et al80 where the inducible 
Clindamycin resistance was 18%.  Deotale et al,81found  27.6% inducible 
Clindamycin resistance among MRSA isolates. This is in contrast to the 
studies by Ajantha et al,82where 74%  of MRSA were positive for D-test. 
 Constitutive resistance was observed in 6% of MRSA isolates in 
the present study. But the study by Angel et al83 had found that none of 
the MRSA isolates exhibited it. Detection of inducible Clindamycin 
resistance has a pivotal role in the clinical laboratories as it helps to avoid 
therapeutic failure. 
6.5.4. Gentamicin            
 Gentamicin resistance was 18 (27.3%) among MSSA isolates and 
24 (70.6%) among  MRSA isolates. Terry Ali et al53 had found 56.5% 
resistance and the study from Manglore61 found 40-50% of the MRSA 
isolates were resistant to Gentamicin.  A 100% resistance was observed 
among the MRSA isolates in the study from Assam.71 But the study by 
Rajaduraipandi et al40   had reported 20.5% to Gentamicin among MRSA 
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isolates.  Among Aminoglycosides, the role of Gentamicin for MRSA 
infections can be ruled out, as it is frequently administered for Gram 
negative infections. 
6.5.5. Amikacin                  
 In this study, 7 (10.6%) resistance among MSSA isolates and 12 
(35.3%) among MRSA isolates was noted for Amikacin.  This is similar 
to the study from Amristar,26 where the resistance to Amikacin was 12 
(8.9%) among MSSA isolates and 43 (37.4%) among MRSA isolates. 
This is in opposition to the study by Mullah et al,36 where the Amikacin 
resistance was found to be 52.6%. But a recent study from Iran,84 had 
showed only 13.8% resistance. Amikacin still remains effective for 
MRSA infections. 
6.5.6. Ciprofloxacin                 
 Resistance to Ciprofloxacin is considered to be surrogate marker 
for MRSA infections. In this study, Ciprofloxacin resistance was found to 
be 64.7% among MRSA isolates.  The study by Rao et al61 found 53-56% 
resistance for Ciprofloxacin among MRSA isolates. The study by Pai et 
al70 found only 31.8% resistance among MRSA isolates. Quershi et 
al,52found higher resistance among MRSA isolates (90%) to 
Ciprofloxacin. 
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6.5.7. Vancomycin               
 In the present study, all the isolates were sensitive to Vancomycin. 
This is similar to the studies by Terry Alli et al53 and Arora et al,26 where 
Vancomycin resistance was not found among MRSA isolates. This is in 
contrast to the study by Assadullah et al,33 where 4 (3.3%) isolates had 
low level resistance to vancomycin among MRSA isolates. Vancomycin 
is the reserve drug for serious MRSA infections. DD method for 
Vancomycin has to be confirmed with agar screen, dilution or molecular 
methods as per CLSI guidelines.67 
 6.5.8. Teic oplanin              
 Resistance to Glycopeptides like Teicoplanin is of concern today, 
since only a handful of drugs are available for MRSA infections. 
Teicoplanin resistance was noted in an isolate of MRSA in the present 
study. The studies from India,34,54had found 100% sensitivity among 
MRSA isolates to Teicoplanin. 
6.5.9. Linezolid                  
 All the isolates were susceptible (100%) to Linezolid. The study by 
Srinivasan et al44 found that all the MRSA isolates were susceptible to the 
drug. Rajaduraipandi et al40, found that 97.6% of the MRSA isolates were 
sensitive to this drug. Linezolid remains as an effective drug for MRSA 
infections.   
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6.6. Multidrug resistance 
 In this study, seven (20.5%) isolates had resistance to six drugs 
tested while four (11.7%) had resistance to five of the drugs tested. 
Multidrug resistance was noted among 21% of the MRSA isolates. This is 
similar to the study by Majumer et al,71 where 23.2% multidrug resistance 
was reported among MRSA isolates. Zeinalli et al84 too confirmed the 
multidrug resistance among 87 MRSA isolates. 
 Multidrug resistance was observed more among MRSA isolates 
than MSSA isolates. In the present study, multidrug resistance was noted 
for the following drugs like Erythromycin, Clindamycin, Gentamicin, 
Amikacin, Ciprofloxacin and Co-trimoxazole. These are considered as 
the first line treatment for MRSA infections and their resistance is of 
major concern as treatment goes in favour of glycopeptides, which are the 
reserve drugs and a bit costly too. This can give rise to unexpected 
outbreaks in hospital. 
 The present study revealed that the Chromagar was highly sensitive 
and specific for detecting Methicillin resistance. It is equally efficacious 
in detecting Methicillin resistance to Cefoxitin DD method. The 
colouration of the colonies makes visual interpretation so easy. In clinical 
laboratories, with lacking technical facilities, disc based tests consume 
ample time in processing. Chromagar attempts to reduce this and so this 
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method can reliably be used as an alternative where mecA gene detection 
is not feasible. 
 The marked difference between the antibiogram of MRSA and 
MSSA isolates makes difficult to interpret routine antibiotic susceptibility 
testing of S.aureus. The multidrug resistance of MRSA isolates is of 
alarming problem. Difficulty in deciding the initial treatment exists for 
S.aureus and so it is wise to perform antibiotic sensitivity testing for all 
S.aureus isolates before initiating treatment. The effort for manufacturing 
newer antibiotic for Gram positive infections remains uncertain and only 
fewer antimicrobials remains as alternatives.  An integrated awareness 
program, good hand washing techniques along with frequent 
epidemiological studies and effective control measures are the goals for 
MRSA elimination in hospitals in the future.  
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7. SUMMARY 
 This study was undertaken at Tirunelveli Medical College, 
Tirunelveli for a period of one year from 100 S.aureus isolates isolated 
from pus samples. These isolates were assessed for the antibiotic 
sensitivity pattern and Methicillin resistance by Cefoxitin DD method, 
Chromagar and  PCR and the various risk factors were analysed. 
 A total of 62 isolates of S.aureus, were from males and the 
remaining 38 were from females. 
 Cefoxitin DD method identified 34 MRSA isolates by 
measuring the zone size of ≤ 21 mm in diameter. 
 The sensitivity and specificity of Cefoxitin DD method was 
100 % while PPV and NPV were 100% respectively. 
 Chromagar showed growth of bluish green colonies for the 
same 34 isolates. 
 The sensitivity and specificity of Chromagar was 100 % while 
PPV and NPV were 100% respectively. 
 Real time PCR detected mecA gene in the 34 isolates which is 
considered the ‘gold standard’ in this study. 
 The prevalence of the MRSA isolates from pus samples was 
34%. 
 A total of 25% of the MRSA isolates were from males and 9% 
were from females. 
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 Mean age of the MRSA isolates from male was 30.7 years and 
that of female was 39.2 years which was not considered 
significant. 
 Most of the MRSA isolates 9 (36%) were from ≤ 15 years of 
age of which all were boys. 
 No significant association was found between inpatients and 
outpatients. 
 Surgery accounted for 11 (32.3%) of the MRSA isolates while 
seven (20.6%) from paediatrics and four (11.8 %) were from 
orthopaedics. 
 Wound infections constituted majority 10 (29.4%) of the 
infections by MRSA isolates followed by surgical site 
infections nine (26.5%) and boil/ furuncle seven (17.6%). 
 Duration of stay at hospital for more than two weeks had no 
significant association with the MRSA infection. 
 The associated risk factors for MRSA infection were surgery 
(26.5%), diabetes (11.8%), burns, HIV and Job’s syndrome 
each one (2.9%) respectively. 
 Only four (6.1%) of the MSSA isolates were sensitive to 
Penicillin. 
 A total of five (7.6%) of the MSSA isolates and 21 (61.8%) of 
the MRSA isolates were resistant to Erythromycin. 
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 Resistance to Gentamicin were noted with 18 (27.3%) of 
MSSA isolates while it is 24 (70.6%) of the MSSA isolates.  
 A total of 13 (38.2%) of the MRSA and 52 (78.8%) of the 
MSSA isolates were sensitive to Amikacin. 
 Resistance was shown by 29 (44%) of the MSSA isolates and 
22 (64.7%) of the MRSA isolates to Ciprofloxacin. 
 A total of 22 (42.4%) were susceptible among MSSA and 10 
(29.4%) among MRSA isolates to Co-trimoxazole. 
 All the isolates both MSSA and MRSA were sensitive to 
Vancomycin, Tigecycline and Linezolid. 
 Resistance was shown by an MRSA isolate to the 
Glycopeptide, Teicoplanin. 
 Inducible Clindamycin resistance was 12% and constitutive 
resistance was 6% among MRSA isolates while 3% of the 
MSSA isolates were positive for D-test. 
 Multidrug resistance was noted among 21% of the MRSA 
isolates to the commonly used drugs like Erythromycin, 
Ciprofloxacin, Clindamycin, Gentamicin, Amikacin And Co-
trimoxazole. 
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8. CONCLUSION 
 
 This study highlights the prevalence of MRSA among clinical 
samples conditioning the patient for prolonged treatment and 
associated risk factors adds to the problem. 
 Antibiogram of Methicillin sensitive and resistant isolates differs 
and susceptibility testing is mandatory for clinical isolates of 
S.aureus before initiation of treatment as few antibiotics exist for 
serious MRSA infections. 
 DD methods are easy to perform and cost effective in Methicillin 
resistance detection and is the standard procedure which tends to 
be followed in many laboratories. 
 Chromagar is to be considered as a diagnostic tool for Methicillin 
resistance because of its rapid and easy interpretation, high 
sensitivity and specificity and lack of skill in performing the 
method. 
 Real time PCR continues to remain as “gold standard” for mecA 
gene detection because of its high specificity. 
 An approach to eliminate MRSA in the hospitals and community 
needs to be integrated by creating awareness among people and 
good hygienic practices and effective barrier precautions are to be 
adapted to prevent further transmission. 
SL.NO Age IP/OP Sex Ward Diagnosis Duration Risk
 factors
Peni
cillin
Methi
cillin
Erythro
mycin
Clinda
mycin
Genta
mycin Amikacin
Cipro
floxacin
Sep
tran
Van
comycin
Teico
planin
Line
zolid
Tige
cyline
CHRO
Magar PCR Ct Value
1 26 IP M surgery wound infection 2 weeks - R R R S I I S I S I S S + + 23.17
2 25D IP M surgery wound infection 2 weeks - R R I S R I I I S I S S + + 15.21
3 8 IP M paediatrics wound infection 2 weeks - R S I S S S S R S S S S -
4 11 IP M paediatrics wound infection 2 weeks - R S I S R I R R S I S S -
5 37 IP F surgery abscess 2 weeks - R R R R(D test) I S R S S S S S + + 16.14
6 52 IP F surgery wound infection 2 weeks diabetes R S S S S S S I S S S S -
7 45 IP F surgery wound infection 2 weeks diabetes R S R R(D test) R R R R S I S S -
8 36 IP F ENT ear discharge 2 weeks - R S I S R S R R S S S S -
9 15 IP M surgery surgical site inf 2 weeks surgery R S S S S S S S S S S S -
10 40 IP M ortho wound infection 2 weeks - R R I R S S S S S S S S + + 14.13
11 29 IP M surgery surgical site inf 2 weeks - R S I I S R S S S S S S -
12 67 IP M surgery wound infection 2 weeks - R S S I S S S S S S S S -
13 35 IP F surgery surgical site inf 2 weeks surgery R R R R(D test) S S R S S S S S + + 14.35
14 17 IP M surgery abscess 2 weeks - R S I I S S S I S I S S -
15 12 OP M ENT ear discharge - - R S I I S S S S S I S S -
16 42 IP M surgery surgical site inf 2 weeks surgery R S I I S S S I S S S S -
17 38 IP M surgery abscess 2 weeks - R R I R S I I S S R S S + + 13.22
18 8 IP F paediatrics boil 2 weeks - R S S S S S S S S S S S -
19 60 IP M surgery surgical site inf 2 weeks diabetes R S R R(D test) R R R I S R S S -
20 31 IP M ortho wound infection 2 weeks - R S R R(D test) R R R I S I S S -
21 46 IP M surgery surgical site inf 2 weeks surgery R R I I R R I S S S S S + + 14.78
22 32 IP F surgery burns 2 weeks burns R R S S S S S S S I S S -
23 6D IP F paediatrics wound infection 2 weeks - R S I I S S S S S I S S -
24 50D IP M paediatrics boil 2 weeks - R R I I S S S S S S S S + + 14
25 27 IP M ortho surgical site inf 2 weeks surgery R S S I S S I S S S S S -
26 60 IP M surgery wound infection 2 weeks diabetes R R R R(D test) R R R R S I S S + + 19.65
27 72 IP M ortho surgical site inf 2 weeks diabetes R S S S S S S S S S S S -
28 49 IP M ortho surgical site inf 2 weeks surgery R S I S R R R I S I S S -
29 3 IP M paediatrics surgical site inf 2 weeks surgery R R R R(D test) R R R R S S S S + + 15.57
30 29 IP M ortho surgical site inf 2 weeks surgery R S I S S S S I S S S S -
31 75 IP M surgery surgical site inf 2 weeks surgery R S S S S S R S S I S S -
32 57 IP M skin boil 2 weeks diabetes R R S S R S R I S S S S + + 11.89
33 32 IP F surgery surgical site inf 2 weeks surgery R S I S R I R R S S S S -
EVALUATION OF CHROMAGAR AND PCR FOR DETECTION OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 
FROM CLINICAL ISOLATES
ANNEXURE -III  MASTER CHART
34 48 IP M skin boil 2 weeks - R S I S R I R I S S S S -
35 8 IP F skin boil 2 weeksjob syndrome R R I I R I R R S I S S -
36 59 OP F surgery abscess - - R S I S S S R S S S S S -
37 4 IP M paediatrics wound infection 2 weeks - R R I S S I R R S I S S + + 16.35
38 36 IP M ortho surgical site inf 2 weeks surgery R R R R(D test) R R R R S I S S + + 14.7
39 33 IP M ortho surgical site inf 2 weeks surgery R S I S R S I S S S S S -
40 23 IP F OG surgical site inf 2 weeks surgery S S S S S S S S S S S S -
41 15D IP F paediatrics wound infection 2 weeks - R S I S R I I I S S S S -
42 45 IP M surgery carbuncle 2 weeks diabetes R S S S R S I S S S S S -
43 45 IP M surgery burns 2 weeks burns R S I S I S R I S S S S -
44 11 IP F paediatrics abscess 2 weeks - R S S I R S R I S S S S -
45 2 IP F paediatrics boil 2 weeks - R S S S S S S S S S S S -
46 74 IP F ENT ear discharge 2 weeks - R S I S R S R S S S S S -
47 46 IP F skin boil 2 weeks - R R R R(D test) R R R R S S S S + + 22.44
48 41 IP M ortho surgical site inf 2 weeks surgery R S S S S S S I S S S S -
49 20 IP F OG surgical site inf 2 weeks surgery R R R R(D test) R I R R S S S S + + 13.27
50 8 IP F skin boil 2 weeks - R S I S R S R I S S S S -
51 70 IP F ophthal abscess 2 weeks - R R R R(D test) R R R I S S S S + + 16.35
52 15D IP F paediatrics abscess 2 weeks - R S I S S S R S S I S S -
53 3 OP F paediatrics abscess - - R S S S I S I R S S S S -
54 55 IP M ortho surgical site inf 2 weeks surgery R R R R(D test) R S I R S S S S + + 12.93
55 65 IP M neurosurgery abscess 2 weeks - R R R R(D test) R I R R S S S S + + 17.3
56 12 IP M ortho surgical site inf 2 weeks surgery R S I S S S R I S S S S -
57 19 IP M surgery abscess 2 weeks - R R I S R S R R S S S S + + 19.36
58 11 IP M paediatrics boil 2 weeks - R R I S S S R R S S S S + + 14.04
59 15 IP M surgery wound infection 2 weeks - R S I S S S R S S I S S -
60 57 IP M surgery wound infection 2 weeks diabetes R R R R(D test) R R R R S I S S + + 20.08
61 25 IP F OG surgical site inf 2 weeks surgery S S S S S S R R S I S S -
62 30 IP M ortho surgical site inf 2 weeks surgery R S I S S S R R S S S S -
63 55 OP F ortho surgical site inf - surgery R R R S R R R R S I S S + + 36.56
64 67 OP M surgery carbuncle - diabetes R R R S R I R I S I S S + + 20.03
65 16 IP F ENT ear discharge 2 weeks - R S I I I S R I S I S S -
66 11 OP M ENT ear discharge - - R S I I R S R I S I S S -
67 29 IP M ortho surgical site inf 2 weeks surgery R S S S S S S S S I S S -
68 45 IP F ENT ear discharge 2 weeks - R S I S S S R I S I S S -
69 12 IP M ENT ear discharge 2 weeks - R R I S R S R R S S S S + + 17.14
70 19 IP M surgery wound infection 2 weeks - R S I S S S S S S I S S -
71 1 IP F paediatrics abscess 2 weeks - R S R S S S S S S I S S -
72 65 IP F medicine abscess 2 weeks diabetes R S S I S R I R S S S S -
73 15 IP F medicine abscess 2 weeks - R S I S S S I I S I S S -
74 60 IP M ortho surgical site inf 2 weeks surgery R S I I S R I R S S S S -
75 25 IP M ENT ear discharge 2 weeks - R R R I R S R R S S S S + + 15.03
76 1 IP M paediatrics wound infection 2 weeks - R R R R R R R R S I S S + + 15.4
77 35 IP F OG surgical site inf 2 weeks surgery R R R R R R I I S I S S + + 36.05
78 82 IP M skin boil 2 weeks - R S I S S S R R S S S S -
79 14 IP F surgery surgical site inf 2 weeks surgery R S I S S S R R S I S S -
80 31 IP F ENT ear discharge 2 weeks - R R I I R I I I S I S S + + 16.65
81 47 IP M ortho surgical site inf 2 weeks surgery R S I S S S R S S S S S -
82 48 IP F surgery surgical site inf 2 weeks diabetes R S R S S I R R S S S S -
83 12 IP M paediatrics wound infection 2 weeks - R R R R R R I S S S S S + + 18.61
84 24 IP F OG surgical site inf 2 weeks surgery R R R I I S R S S I S S + + 15.38
85 35 IP M surgery wound infection 2 weeks - R S I I S S R R S I S S -
86 40 IP M surgery surgical site inf 2 weeks surgery R S I S S S I I S I S S -
87 60 IP M ortho surgical site inf 2 weeks surgery R S I S S S I S S I S S -
88 70 IP M surgery wound infection 2 weeks - R S S S S S I S S S S S -
89 52 IP M skin wound infection 2 weeks - R R I S R S I I S S S S + + 14.47
90 36 IP M skin boil 2 weeks - R R R R(D test) R I R I S S S S + + 16.7
91 3 IP F paediatrics burns 2 weeks burns R S S I S S S S S S S S -
92 47 IP F ortho surgical site inf 2 weeks surgery R S I I S S S S S S S S -
93 45 IP M skin boil 2 weeks HIV R R I S R S I S S S S S + + 15.79
94 5 IP M paediatrics abscess 2 weeks - R S I I S S I S S S S S -
95 26 IP F OG surgical site inf 2 weeks surgery R S S S S S I R S S S S -
96 1 IP M paediatrics wound infection 2 weeks - R R R R R R R R S S S S + + 21.15
97 67 IP M ENT ear discharge 2 weeks - R S I S R I R I S S S S -
98 43 IP M surgery wound infection 2 weeks diabetes S S S S S S S S S S S S -
99 3 IP F paediatrics boil 2 weeks - S S S S S S I S S S S S -
100 68 IP M ortho surgical site inf 2 weeks surgery R S I S I S I R S S S S -
 MRSA
<2 weeks 78.1
>2 weeks 21.9
To resize chart data range, drag lower right corner of range.
Risk 
factors Pecentage
Surgery 26.5
Diabetes 11.8
Burns 2.9
Job’s 
syndrome
2.9
30
40
50
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100
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Total 100
 inducible constitutive 
MSSA 3 0
MRSA 12 6
0
10
20
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HIV  
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Total
0
2
4
6
8
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3
0
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6
MRSA
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MRSA
≤ 2  drugs 38.2
3 drugs 14.7
4 drugs 14.7
5 drugs 11.7
6 drugs 20.5
0
5
10
15
20
25
30
35
40
≤ 2  drugs 3 drugs 4 drugs 5 drugs 6 drugs
38.2
14.7 14.7
11.7
20.5
≤ 2  drugs
3 drugs
4 drugs
5 drugs
6 drugs
ABBREVIATIONS 
 
  S.aureus  -  Staphylococcus aureus 
  MRSA  -  Methicillin Resistant Staphylococcus aureus 
                    MSSA                    -         Methicillin Sensitive Staphylococcus aureus 
  HA-MRSA  -  Hospital acquired MRSA 
  CA-MRSA  -  Community acquired MRSA 
  PBP   -  Penicillin Binding Protein  
  SCCmec  -  Staphyloccocal Cassette Chromosome mec 
  PVL                       -          Panton-Valentine Leucocidin 
  CLSI   -  Clinical Laboratory Standards Institute 
  DD test  -  Disc diffusion test 
  PCR   -  Polymerase Chain Reaction 
  NPV   -  Negative Predictive Value 
  PPV   -  Positive Predictive Value 
  Ct value  -  Cross threshold value 
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Annexure –I 
(Media preparation) 
1.Preparation of Mueller-Hinton agar  
 Composition                                     gms/l 
               Beef infusion, from         -  300  
               Casein acid hydrolysate    - 17.5 
               Starch                                 - 1.5  
              Agar                                    -  17.00 
              Final pH at 25˚C                 - 7.3±0.1 
Preparation 
 Suspend 38.0 grams in 100 ml distilled water. Heat to boiling to 
dissolve the medium completely. Sterilize by autoclaving at 15 lbs 
pressure (121˚C) for 15 minutes. Mix well before pouring. 
2. Preparation of HiCrome MeReSa agar 
 For the isolation and selective identification of Methicillin 
Resistant Staphylococcus aureus (MRSA) from clinical isolates. 
Ingredients                             gms/l 
Casein enzymic hydrolysate -  13.00 
Yeast extract                          -  2.50 
Beef extract                           -  2.50 
Sodium pyruvate                    - 5.00 
Sodium chloride                     -  40.00 
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Chromogenic mixture            - 5.30 
Agar                                       -  15.00 
Final pH (at 25°C) 7.0 ± 0.2 
Directions 
 Suspend 41.65 grams in 500 ml distilled water. Heat to boiling to 
dissolve the medium completely. Do not autoclave. Cool to 45-50°C. 
Aseptically add sterile rehydrated contents of 1 vial of MeReSa Selective 
Supplement.  Mix well and pour into sterile petri plates.  
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  Annexure –2 
(Proforma of the Data sheet) 
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ANNEXURE II 
 
DATA SHEET FOR COLLECTION OF SOCIO DEMOGRAPHIC, 
CLINICAL AND LABORATORY DATA FOR P.G. 
DISSERTATION WORK ON “EVALUATION OF CHROMAGAR 
AND PCR FOR DETECTION OF METHICILLIN RESISTANT 
STAPHYLOCOCCUS AUREUS (MRSA) FROM CLINICAL 
ISOLATES” 
Serial no: 
Name  :                                                                              Lab no:                         
Age/sex:                                                                             IP no:                
Address:        Ward: 
HISTORY                                                                                                
1.Chief complaint :                                                                    
2. H/o Surgery/ RTA/Burns/Others:                                        
3. Duration of hospital stay :                                                    
4. H/o Diabetes/Steroids intake/Chemotherapy/Others:    
GENERAL EXAMINATION 
Built  :                                                                        Pulse: 
Nourishment:                                                               BP: 
Pallor:                                                                                        
Temperature: 
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LOCAL EXAMINATION 
Site :                                                                                               
Induration: 
Size:                                                                                                
Erythema: 
PURULENT DISCHARGE                                                                          
Amount:                                                                                        
Type:     purulent/ blood stained/others 
Colour : 
 Odour:                                                                                                             
INVESTIGATIONS 
Specimen received -  Pus    
1.CULTURE 
Nutrient agar Mac Conkey agar Blood agar 
   
 
2.MICROSCOPY 
 
3.BIOCHEMICAL REACTIONS 
Catalase test  Slide  Coagulase test Tube  Coagulase test 
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4.ANTIBIOGRAM 
             Drug        Zone size           Interpretation 
Penicillin   
Cefoxitin    
Erythromycin   
Clindamycin   
Ciprofloxacin   
Gentamicin   
Amikacin   
Cotrimoxazole   
Vancomycin   
Teicoplanin   
Linezolid   
Tigecyline   
Furazolidone   
 
5.CHROM agar: 
 
 
6.mec A gene :   
 
  
 
